News
Media
Puzzler
Publications
CME/CE
Resources
Conferences
Partnerships
Subscribe
Editorial

|Articles|December 1, 1999

New Products for pediatrics: 1999

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

SL1009 resubmitted to FDA for pyruvate dehydrogenase complex deficiency

SL1009 resubmitted to FDA for pyruvate dehydrogenase complex deficiency

ByMorgan Ebert, Executive Editor

July 8th 2026

FDA expands wilate approval to routine prophylaxis for all types of von Willebrand disease

FDA expands wilate approval to routine prophylaxis for all types of von Willebrand disease

ByMorgan Ebert, Executive Editor

July 8th 2026

FDA accepts roflumilast sNDA for AD in infants aged 3 to 24 months

ByBenjamin P. Saylor

July 8th 2026

FAQ: Which children with early puberty actually need testing and treatment? | Image credit: © Dzmitry - stock.adobe.com.

FAQ: Which children with early puberty actually need testing and treatment?

ByContemporary Pediatrics Staff

July 7th 2026

Researchers identify hypermobility-linked autonomic subtype of eosinophilic esophagitis in children | Image credit: © Yurii Kibalnik - stock.adobe.com.

Researchers identify hypermobility-linked autonomic subtype of eosinophilic esophagitis in children

ByMorgan Ebert, Executive Editor

July 7th 2026

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

FAQ: Which children with early puberty actually need testing and treatment?

Researchers identify hypermobility-linked autonomic subtype of eosinophilic esophagitis in children

FDA clears IND for investigational SUMF1 gene therapy in multiple sulfatase deficiency

FDA accepts roflumilast sNDA for AD in infants aged 3 to 24 months

FDA accepts deucrictibant IR application for on-demand treatment of hereditary angioedema attacks